Alnylam May 2016

11

Transcript of Alnylam May 2016

Page 1: Alnylam May 2016
Page 2: Alnylam May 2016
Page 3: Alnylam May 2016
Page 4: Alnylam May 2016
Page 5: Alnylam May 2016
Page 6: Alnylam May 2016
Page 7: Alnylam May 2016
Page 8: Alnylam May 2016
Page 9: Alnylam May 2016
Page 10: Alnylam May 2016
Page 11: Alnylam May 2016

Corporate Overview (JPM) - Alnylam Pharmaceuticals · Alnylam Forward Looking Statements . This presentation contains forward-looking statements. There are a number of important factors

Corporate Overview (JPM) - Alnylam Pharmaceuticals · Alnylam Forward Looking Statements . This presentation contains forward-looking statements. There are a number of important factors

210922Orig1s000 - Food and Drug Administration · Alnylam Pharmaceuticals Inc. (Alnylam) submitted a New Drug Application ... of the FD&C Act: FDAAA factor (F): ... The clinical presentation

210922Orig1s000 - Food and Drug Administration · Alnylam Pharmaceuticals Inc. (Alnylam) submitted a New Drug Application ... of the FD&C Act: FDAAA factor (F): ... The clinical presentation

Safety Patrol Schedule for April, May and June 2016apetro.weebly.com/uploads/3/0/8/5/30856929/safety_aprmay.pdf · May 23, 2016 May 24, 2016 May 25, 2016 May 26, 2016 May 27, 2016

Safety Patrol Schedule for April, May and June 2016apetro.weebly.com/uploads/3/0/8/5/30856929/safety_aprmay.pdf · May 23, 2016 May 24, 2016 May 25, 2016 May 26, 2016 May 27, 2016

Alnylam Pharmaceuticals Presentation FD

Alnylam Pharmaceuticals Presentation FD

Path to Alnylam 2020 · Path to Alnylam 2020 R&D Day 2015 John Maraganore, Ph.D., Chief Executive Officer . 2 What we’re about: RNAi Therapeutics •Harness natural pathway ...

Path to Alnylam 2020 · Path to Alnylam 2020 R&D Day 2015 John Maraganore, Ph.D., Chief Executive Officer . 2 What we’re about: RNAi Therapeutics •Harness natural pathway ...

May 2016 June 2016 July 2016

May 2016 June 2016 July 2016

4 NBM&CW MAY 2016 NBM&CW MAY 2016 - Creative Group

4 NBM&CW MAY 2016 NBM&CW MAY 2016 - Creative Group

Young Frankenstein - MLOC - May 2016 - Postcardmycommunitylife.com.au/.../young-frankenstein-mloc-may-2016-postcard.pdfTitle: Young Frankenstein - MLOC - May 2016 - Postcard Created

Young Frankenstein - MLOC - May 2016 - Postcardmycommunitylife.com.au/.../young-frankenstein-mloc-may-2016-postcard.pdfTitle: Young Frankenstein - MLOC - May 2016 - Postcard Created

Alnylam 2015 PowerPoint

Alnylam 2015 PowerPoint

Research Initiation Many Shots on Goal Highlights · 2017. 3. 3. · ALN-TTR02 TTR amyloidosis (FAP) phase 3 Alnylam Pharmaceuticals phase 3 results (2016-2017) TKM-Ebola Ebola phase

Research Initiation Many Shots on Goal Highlights · 2017. 3. 3. · ALN-TTR02 TTR amyloidosis (FAP) phase 3 Alnylam Pharmaceuticals phase 3 results (2016-2017) TKM-Ebola Ebola phase

Release Date: June 24, 2016 © In This Issue Seasonally ... · United States Louisiana MAY 2016 MAY 2016 MAY 2016 MAY 2016 United States Louisiana Average Weekly Earnings 1,100.40$

Release Date: June 24, 2016 © In This Issue Seasonally ... · United States Louisiana MAY 2016 MAY 2016 MAY 2016 MAY 2016 United States Louisiana Average Weekly Earnings 1,100.40$

Alnylam Pharmaceuticals Inc RNAi Roundtable: ALN · PDF fileTHOMSON REUTERS STREETEVENTS EDITED TRANSCRIPT ALNY - Alnylam Pharmaceuticals Inc RNAi Roundtable: ALN-AT3 for the treatment

Alnylam Pharmaceuticals Inc RNAi Roundtable: ALN · PDF fileTHOMSON REUTERS STREETEVENTS EDITED TRANSCRIPT ALNY - Alnylam Pharmaceuticals Inc RNAi Roundtable: ALN-AT3 for the treatment

Investigation of Mortality Imbalance in ... - Alnylam DE...revusiran Phase 2 Open Label Extension study (OLE), Alnylam requested ad-hoc ENDEAVOUR Data Monitoring Committee (DMC) meeting

Investigation of Mortality Imbalance in ... - Alnylam DE...revusiran Phase 2 Open Label Extension study (OLE), Alnylam requested ad-hoc ENDEAVOUR Data Monitoring Committee (DMC) meeting

Small Interfering RNAsregist2.virology-education.com/2016/3HBVCure/05_Locarnini.pdf• Alnylam Pharmaceuticals – ALN-HBV (phase 1) ARC-520 consists of 2 vials • Vial 1: ARC-520

Small Interfering RNAsregist2.virology-education.com/2016/3HBVCure/05_Locarnini.pdf• Alnylam Pharmaceuticals – ALN-HBV (phase 1) ARC-520 consists of 2 vials • Vial 1: ARC-520

Alnylam Pharmaceuticals · 12 Patisiran Interim Phase 2 OLE Study Results* Ongoing Study in FAP Patients PLANNED NEXT STEPS 24-month Phase 2 OLE data • in mid-2016 *Preliminary

Alnylam Pharmaceuticals · 12 Patisiran Interim Phase 2 OLE Study Results* Ongoing Study in FAP Patients PLANNED NEXT STEPS 24-month Phase 2 OLE data • in mid-2016 *Preliminary

208025Orig1s000 - Food and Drug Administration...SUBMISSION DATES: May 11, 2016 May 16, 2016 May 20, 2016 May 24, 2016 May 25, 2016 NDA/SUBMISSION TYPE: 208025 ACTIVE INGREDIENTS:

208025Orig1s000 - Food and Drug Administration...SUBMISSION DATES: May 11, 2016 May 16, 2016 May 20, 2016 May 24, 2016 May 25, 2016 NDA/SUBMISSION TYPE: 208025 ACTIVE INGREDIENTS:

May 2016 - TBN Israel - May 2016.pdf · TBN Israel May 2016 Pastor Brian and Cheryl Brodersen with Samuel. TBN Israel May 2016 Live music recording on Studio A. TBN Israel May 2016

May 2016 - TBN Israel - May 2016.pdf · TBN Israel May 2016 Pastor Brian and Cheryl Brodersen with Samuel. TBN Israel May 2016 Live music recording on Studio A. TBN Israel May 2016

MONOGRAPHIE DE PRODUIT - Alnylam

MONOGRAPHIE DE PRODUIT - Alnylam

Corporate Overview - Alnylam Pharmaceuticals › web › assets › ALNY-CorpDeck-PRES-Sept… · Corporate Overview . Alnylam Forward Looking Statements 2 This presentation contains

Corporate Overview - Alnylam Pharmaceuticals › web › assets › ALNY-CorpDeck-PRES-Sept… · Corporate Overview . Alnylam Forward Looking Statements 2 This presentation contains

May 07 - May 13 2016

May 07 - May 13 2016